Adriatic Metals PLC (ASX: ADT) shares finished on a high at the close of trade today, settling 9.8% higher at $2.69 per share. The Adriatic share price peaked at $2.90 mid-afternoon, an all-time high for the miner.

Adriatic Metals share price gets a boost

Investors were driving up the Adriatic Metals share price today after the company announced it has received three new exploration permits. This means the company can now mine more areas in its Vares Project located in Bosnia and Herzegovina. Adriatic Metals is the only listed company mining in the country.

The three permits have expanded the area Adriatic Metals can explore by 32 square kilometres.

The permits were first granted in September last year, sending the Adriatic Metals share price soaring 10.7% on the day of its announcement.

What’s next?

Now, Adriatic Metals plans to commence its exploration at the project. Before applying for the permits to explore the area, the company conducted preliminary sampling. The sampling found seven high-priority targets in the newly permitted areas.

Radiometric surveying has also uncovered a large alteration system under the areas the permits have been received for.

Adriatic Metals has also completed magnetic surveys, which have highlighted additional areas of interest within the new permit zones. The company has already been granted permission to mine using invasive exploration techniques, such as drilling and channel sampling.

A scoping study completed at the Vares Project in 2019 found it has a net value estimation of US$917 million.

Adriatic share price snapshot

Shares in Adriatic Metals are having a great year on the ASX, with today’s gains boosting them to a new all-time high.

The Adriatic Metals share price has gained 15.45% since the beginning of 2021. It has also seen a rise of 91.46% since this time last year.

The company has a market capitalisation of around $496 million, with 210 million shares outstanding.

The post Why the Adriatic Metals (ASX:ADT) share price climbed 10% today appeared first on The Motley Fool Australia.

More reading

• Here’s why the Adriatic Metals (ASX:ADT) share price is gaining today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34VN8D8

The big four banks have been out of favour with investors over the last few years due to the Royal Commission and then the COVID-19 pandemic.

Well, it appears fair to say that the banks are well and truly back in favour with investors now. For example, the Westpac Banking Corp (ASX: WBC) share price is up a stunning 36% since the start of the year.

That’s a return that a rapidly growing tech share like Afterpay Ltd (ASX: APT) would be proud of, let alone Australia’s oldest bank.

Can the Westpac share price still go higher?

The good news is that it may not be too late to invest, with one leading broker tipping the Westpac share price to continue its ascent.

According to a note out of Citi from last month, Westpac remains its sole buy in the sector. The broker currently has a buy rating and $29.50 price target on its shares.

Based on the latest Westpac share price, this implies potential upside of 11% over the next 12 months excluding dividends.

And with Citi forecasting dividend yields of approximately 4.4% in FY 2021 and 4.5% in FY 2022, this potential return stretches beyond 15%.

What did Citi say?

Commenting on Westpac’s half year results, the broker said: “The market received WBC’s 1H21 result positively, with core earnings upgrades near-term from a better than expected NIM; and over the medium term, from lower costs. WBC’s target for FY24 costs of $8bn was lower than we anticipated, and management are confident and ambitious.”

“We see many of the building blocks in place for the strategy, even if obvious sensitivities prevent their more fulsome disclosure. The premise of multi-year core earnings upgrades, layered on sector-wide asset quality improvements, leave WBC with a differentiated investment thesis. It remains our sole Buy in a sector that has rallied strongly in the COVID recovery,” it concluded.

Food for thought for investors looking for banking sector options.

The post Broker tips Westpac (ASX:WBC) share price to keep on rising appeared first on The Motley Fool Australia.

More reading

• ASX 200 Weekly Wrap: ASX hits 7,300 points for the first time
• When the music stops… the investment bankers stop getting paid!
• Why the Westpac (ASX:WBC) share price just hit a 52-week high
• Westpac (ASX:WBC) board to further consider New Zealand demerger
• 2 ASX dividend shares that could help you beat low interest rates

James Mickleboro owns Westpac shares. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34S3f4z

The S&P/ASX 200 Index (ASX: XJO) briefly ticked over 7,300 today for the first time on record. While the big banks and miners were responsible for most of the heavy lifting, these ASX 200 shares have cruised to record all-time highs.

ASX 200 shares making record all-time highs

ARB Corp Ltd (ASX: ARB)

Australia’s largest manufacturer and distributor of 4×4 accessories could be benefitting from some industry tailwinds.

According to Commsec, vehicle sales are bouncing back after COVID-19 induced supply shortages last year. Its report observed that “SUVs and Utes are the wheels of choice, accounting for 8 of the top 10 vehicles sold.”

Taking a broader view, Commsec said that new vehicle sales totalled 100,005 in March, up 22.4% from a year ago.

The ARB share price has run ~11% higher from its February record all-time highs of $40.00. Its shares marked an intraday high of $45.63 and are currently fetching $44.54.

Goodman Group (ASX: GMG)

Goodman has pulled ahead of other ASX-listed REITs today. After an 8-month lull where its share price hovered around the $17 to $19 level, its shave have broke out to record all-time highs this month.

The Goodman share price is up ~5% this month, scoring an intraday record all-time high of $20.77. Its shares have pulled back slightly, currently trading at $20.53.

The last time we heard from Goodman was during its third-quarter update on 7 May. This update included the REIT reaffirming its FY21 guidance of $1.2 billion in operating profit, representing an earnings per share growth of 12% on FY20.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is another ASX 200 share breaking out. Its shares marked an intraday record all-time of $49.81 on Monday and are currently trading at $48.90.

The company’s bullish run has been supported by its continued stream of positive announcements. On 13 May, the company announced an 8-year contract with The University of Vermont Health Network Inc, expected to generate $14 million in revenue. Then on 3 June, the company signed a multi-year research collaboration agreement with Mayo Clinic.

The post ASX 200 shares making record all-time highs today appeared first on The Motley Fool Australia.

More reading

• Best returns in a decade leave experts scrambling to upgrade ASX shares
• $20,000 invested in these ASX shares 10 years ago would be worth how much?
• Why the ARB (ASX:ARB) share price is jumping 7% to a record high
• Why ARB, Humm, Incitec Pivot, & Pro Medicus shares are charging higher
• ASX 200 up 0.1%: Tech shares fall, gold miners tumble

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended ARB Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/2T6ZhCd

The Airtasker Ltd (ASX: ART) share price was a positive performer on Monday.

At one stage today, the local jobs marketplace provider’s shares were up 5% to $1.20.

When the Airtasker share price reached that level, it meant it was up 85% from its March IPO listing price of 65 cents.

Why did the Airtasker share price charge higher?

With no news out of the company, today’s gain appears to have been driven by a bullish broker note out of Morgans this morning.

According to the note, the broker has upgraded the company’s shares from a neutral rating to an add rating with an improved price target of $1.29.

Based on its Friday’s close, this implied potential upside of just over 13% for the Airtasker share price over the next 12 months.

Why did Morgans upgrade its shares?

Morgans made the move largely on the surprisingly strong progress the company is making in the UK and US markets.

In respect to the latter, the broker notes that there are positive signs of traction in the US market, with tangible evidence of demand picking up. For example, Morgans estimates that there was an average of 225 tasks posted weekly last month across its US business. This was despite Airtasker not spending money on advertising in the lucrative market.

In light of this, it appears pleased with the company’s decision to acquire the US-based Zaarly business recently.

With established operations and user bases in two US cities, the broker believes Zaarly will support the development of a US marketplace.

Is anyone else positive on Airtasker?

As my colleague revealed here last month, the Firetrail Small Companies Fund is also positive on Airtasker.

Firetrail’s equity analyst, Eleanor Swanson, commented on LiveWire: “Users create their own unique tasks and communicate the requirements directly to taskers. The flexibility is valued by both customers and taskers, reflected by the fact that a new task is posted on Airtasker every 17 seconds. In addition, the company is now the number 1 employer of platform workers in Australia, ahead of even Uber!”

“The company aims to reach over 80% brand awareness within the next 2 years. Heightened brand awareness will drive increased market penetration and growth in total transaction value on the marketplace,” she added.

Swanson also highlighted the company’s huge market opportunity globally, which is estimated to be worth $643 billion.

The post Why the Airtasker (ASX:ART) share price charged 5% higher appeared first on The Motley Fool Australia.

More reading

• Leading brokers name 3 ASX shares to buy today
• The Airtasker (ASX:ART) share price has fallen 11% in a month
• These 2 growing ASX shares have upgraded guidance
• ASX 200 rises, TechnologyOne up, Airtasker jumps
• Why the Airtasker (ASX:ART) share price jumped 21% today

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Airtasker Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3uYbpD0

There are some interest ASX shares out there that currently offer relatively high dividend yields at the current prices.

Income might be harder to come by in the current environment with how low the official interests are right now. Just look at how low the Reserve Bank of Australia (RBA) rate is – it’s almost 0%.

But these two businesses could provide a useful income boost:

Charter Hall Long WALE REIT (ASX: CLW)

This real estate investment trust (REIT) is an ASX share that looks to provide investors with a distribution payout ratio of operating earnings of 100%. That has the effect of producing a higher yield (compared to if the payout ratio was lower).

It’s invested in a number of different commercial real estate sectors including long WALE retail, office, industrials and logistics, social infrastructure and agri-logistics. It has a property portfolio WALE of 13.8 years and an occupancy rate of 97.7%. The overall value of the portfolio is $5.3 billion with a weighted average rent review of 2.3%.

The ASX share recently announced that it has entered into agreements to acquire 50% interests in three modern, long WALE suburban office properties and one modern life sciences property.

Those acquisitions include the Services Australia building in Tuggeranong, ACT, for $153 million, the ATO building in Box Hill, Victoria, for $115 million, the Red Cross building in Alexandria, NSW, for $79.5 million and the ATO building in Albury, NSW, for $42.5 million. These acquisitions come with a WALE of 9.2 years and WARR of 3.6% per annum.

Charter Hall Long WALE REIT upgraded its operating earnings per share (EPS) guidance to 29.2 cents per security, which would be growth of 3.2% over FY20 and would equate to a distribution yield of 6%. Management expect FY22 operating EPS to grow by at least 2.75%.

It’s currently rated as a buy by the brokers at Citi.

Adairs Ltd (ASX: ADH)

Adairs is one of the largest retailers in the country of homewares and furnishings products.

The business is pursuing an array of different growth avenues. It’s looking to grow its online sales to customers by investing in its digital capabilities. This is producing results with Adairs FY21 half-year online sales increasing 95.2% and Mocka online sales rising 44.4% to $28 million. Total online sales were $90.2 million, representing 37.1% of group sales.

Adairs is also focused on margin improvement at all levels of the business. This is helping grow the bottom line significantly. HY21 saw sales rise 34.8%, the gross margin improved 500 basis points, underlying group earning before interest and tax (EBIT) rose 166.2% to $60.2 million and statutory net profit jumped 233.4%.

In the half-year, Adairs generated EPS of 25.9 cents. This allowed it to fund an interim dividend of 13 cents per share to shareholders.

Adairs is looking to open a new national distribution centre and open larger stores to grow margins and profit further.

At the current Adairs share price, it offers a projected grossed-up dividend yield of 7.9% for FY21, according to Commsec.

The post Got cash to invest for dividends? Here are 2 ASX shares that could be buys appeared first on The Motley Fool Australia.

More reading

• Got money to invest for dividends? Here are 2 ASX shares that could be buys
• 2 ASX 200 dividend shares that could offer good income
• 2 ASX shares with BIG dividend yields
• Why the Charter Hall REIT (ASX:CLW) share price is frozen
• 2 ASX dividend shares to buy with yields above 5%

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ADAIRS FPO. The Motley Fool Australia has recommended ADAIRS FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34XcdNM

The market is running out of puff but these ASX shares may have more things to worry about after they got downgraded by to brokers.

The S&P/ASX 200 Index (Index:^AXJO) slipped 0.1% into the red during lunch time trade after gaining 0.2% this morning.

ASX financial shares are leading the sell-off but the Cleanaway Waste Management Ltd (ASX: CWY) share price is also underperforming.

Overstretched valuation for this ASX share triggers downgrade

The Cleanaway share price fell 2.9% in the last hour of trade to $2.66 after Credit Suisse downgraded the waste management company to “underperform” from “neutral”.

The broker’s sell call comes after the shares recently hit its highest level since 2008. The market has gotten excited about Cleanway’s move to acquire Suez’s Sydney operations.

The deal looks set to go though as Cleanaway does not own any putrescible landfills in Sydney, noted the broker.

Getting cleaned out

However, Credit Suisse believes market expectations for the Cleanaway share price is set too high.

“Cleanaway recently guided to A$10-15mn lower EBITDA contribution from its New Chum landfill in FY22 due to planned lower volumes to avoid triggering end-of-life rehabilitation costs, before it secures a height extension,” said the broker.

“We interpret this to mean that management thinks FY22 consensus forecasts are too high.”

Credit Suisse lowered its FY22 EBITDA forecast by 4% to $570 million. This is due to lower contribution from New Chum and a slower than expected post-COVID-19 recovery.

As a result, the broker’s 12-month price target on the Cleanaway share price falls by 10 cents to $2.40 a share.

ASX mining share’s golden run hit by downgrade

Another that may have run ahead of fundamentals is the Fortescue Metals Group Limited (ASX: FMG) share price.

Morgans reckons now is the time to lock in profits as it downgraded the iron ore producer to “reduce” from “hold”.

It’s bearish outlook for the Fortescue share price is partly driven by the belief that the iron ore price has past its prime – at least for now.

Rising cost as iron ore price peaks

The broker also believes that cost inflation is a particular problem for miners that operate in the Pilbara.

Fortescue could be hit harder than most too. Not are its mines in the Pilbara, but it is currently undertaking a massive expansion project called Iron Bridge.

How much is the Fortescue share price worth?

“After a remarkable run, and hefty shareholder returns, we see the risk/reward balance for FMG finally skewed to the downside,” said Morgans.

“A mass-scale low-grade pure iron ore producer, and fledgling energy aspirant, we see FMG as being particularly sensitive to a maturing iron ore cycle.”

The Fortescue share price surrendered strong early gains to trade 1% in the red at $22.73 ahead of the market close.

Morgan’s 12-month price target on Fortescue is $18.70 a share.

The post These ASX shares just got hit with a broker downgrade today appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are on the move today
• Do higher interest rates look more likely than ever now?
• Crown (ASX:CWN) share price under pressure from AUSTRAC enforcement investigation
• ASX 200 down 0.1%: Altium rockets, NAB hit with AUSTRAC investigation
• How has the Telstra (ASX:TLS) share price jumped to a 52-week high

Brendon Lau owns shares of Fortescue Metals Group. Connect with me on Twitter @brenlau.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3fXRu2F

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an update on its clinical pipeline. In afternoon trade, shares in Recce Pharmaceuticals are trading 0.46% lower at $1.08.

The update announced delays to the company’s overseas COVID-19 animal studies.

Let’s take a closer at today’s news.

Recce’s clinical pipeline update

COVID-19 studies

According to Recce, overseas studies testing the efficacy of its RECCE 529 on animals infected with COVID-19 variants has been delayed.

RECCE 529 is a synthetic anti-infective which has, to date, been studied as a treatment for COVID-19.

Some of the studies testing the ability of RECCE 529 to treat COVID-19 variants are experiencing delays, as labs struggle to infect ferrets with the variants.

Despite this, the company believes it will have data on the effectiveness of RECCE 529 against the UK and South African COVID-19 strains by the fourth quarter of 2021.

Meanwhile, Reece’s other synthetic anti-infective which has proven to be promising against COVID-19, R327, has shown more encouraging results. It has moved to the second stage of its Australian study, with results due late this year.

Burns trial

Also underway is a human clinical trial using R327 to treat burns. The eight-month trial is being conducted at Fiona Stanley Hospital in Perth, Western Australia.

Recce expects data from the burns trial to be available in the fourth quarter of 2021.

Intravenous trial

R327 is also being injected intravenously in the first phase of a human clinical trial.

According to Recce, so far, injecting R327 intravenously has been found effective in treating sepsis, kidney infections, and urinary tract infections.

The first trial will see healthy patients dosed with R327 in August 2021. Recce expects interim data from the intravenous trial late this year. Full results are likely to be available mid-2022.

Helicobacter pylori pre-clinical studies

Finally, Recce Pharmaceuticals updated the market on its oral compound (RECCE 435) designed to fight helicobacter pylori infections.

The company is currently testing RECCE 435 on mice, and expects results from the pre-clinical study in mid-2022. Recce hopes the results will lead to a clinical study next year.

Recce share price snapshot

The Recce Pharmaceuticals share price has been bobbing along on the ASX so far this year. The most notable peaks were $1.26 and $1.19 in mid-April and early May respectively.

Currently, the Recce Pharmaceuticals share price is up by around 3% year to date. It has gained 32% since this time last year.

The company has a market capitalisation of around $185 million, with approximately 173 million shares outstanding.

The post Recce (ASX:RCE) share price edges lower following study delays appeared first on The Motley Fool Australia.

More reading

• Why the Recce (ASX:RCE) share price is surging 8% higher today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3ghnuh5

Often the biggest risers and fallers of the S&P/ASX 200 Index (ASX: XJO) dominate investors attention on any given day. But it’s also very interesting to look at the ASX 200 shares that are dominating trading volume. These most traded ASX shares can help us understand what is moving the markets, and sentiment, on any given day.

So with that in mind, let’s take a look at the ASX 200 shares that are swapping hands with the most volume today:

3 ASX 200 shares on the move today

Cleanaway Waste Management Ltd (ASX: CWY)

Cleanaway Waste is on the move today, with 7.25 million shares traded today at the time of writing. That’s probably the result of the Cleanaway share price falling a hefty 2.92% today to $2.66 a share. Since Cleanaway is a $5.5 billion ASX 200 company, a move of this size will inevitably result in some heavy trading activity.

There’s no obvious reason why Cleanaway is falling today though since no major news or announcements have come out of the company. Perhaps investors are in the mood for some profit-taking, seeing as Cleanaway is still up more than 21% over the past 2 months.

National Australia Bank Ltd. (ASX: NAB)

NAB shares have also been thrown around today, with 8.28 million shares traded at the time of writing. This ASX 200 bank is not having an enjoyable day. NAB shares are down 2.96% to $26.70 after spending last week rising towards its 52-week high.

Unlike Cleanaway, we might know what’s going on here though. As we discussed earlier today, NAB has just revealed that it’s under investigation by AUSTRAC regarding alleged “potential serious and ongoing non-compliance” with anti-money laundering regulations. It’s no surprise that a development like that has sparked some heavy trading.

Pilbara Minerals Ltd (ASX: PLS)

Pilbara Minerals is currently the most heavily traded ASX share in the ASX 200 Index. A whopping 13.9 million shares have swapped hands today so far. The Pilbara share price has bounced around today but is still up 2.44% currently to $1.34 a share – not too far off of its 52-week high of $1.47.

Like Cleanaway, there is no major news out today that may have sparked these volumes. However, there are many investors that are interested in lithium companies like Pilbara, considering the mineral’s role in electric vehicle batteries. In fact, Pilbara shares are now up more than 24% in just the past fortnight.

The post These 3 ASX 200 shares are on the move today appeared first on The Motley Fool Australia.

More reading

• Why Flight Centre, Mesoblast, NAB, & SkyCity shares are sinking
• Do higher interest rates look more likely than ever now?
• Star (ASX:SGR) share price latest to fall on anti-money laundering investigation
• Crown (ASX:CWN) share price under pressure from AUSTRAC enforcement investigation
• ASX 200 down 0.1%: Altium rockets, NAB hit with AUSTRAC investigation

Motley Fool contributor Sebastian Bowen owns shares of National Australia Bank Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/34S1Bjt

The Globe Metals & Mining Limited (ASX: GBE) share price is up a staggering 207.69% to 12.5 cents at the time of writing. Globe shares closed at just 3.9 cents last week and opened at 5 cents this morning before having a rocket lit under them.

At one point during early afternoon trade, the company’s shares had rallied by almost 368% to 16.5 cents apiece before retreating to their current level.

What is this company?

Globe Metals & Minerals is an ASX resources company focused on resource exploration and development primarily in Africa. Its flagship project is the Kanyika Niobium Project in Malawi.

Globe Metals has been an ASX-listed company since June 2016. Until late last year, the company’s share price hadn’t really done anything remarkable. Globe shares spent a few years bumping along around 1 to 2 cents per share. But things turned around in October when Globe hit 3 cents per share and 4 cents by December.

Globe Metals shares were actually in a trading halt since Friday morning. At the time, the company said shares would resume trading on 8 June at the latest, pending an announcement. Well, we got the said announcement this morning.

So what’s going on with the Globe Metals & Mining share price today?

Globe released a statement around market open this morning. In this statement, the company informed investors the Malawi Government’s Mineral Resources Committee has reviewed Globe’s mining licence application for its Kanyika Niobium Project. The recommendation is for the grant of a mining licence.

According to Globe, this recommendation is a “critical and formal step” in obtaining a full license for its project. The company “now awaits receipt of the mining licence and subsequent execution of the Development Agreement with the Government of Malawi”.

Globe also told the markets it “is of the understanding that the licence will have a mining lease term of 25 years from the date of issue consistent with the Mines Act”.

Here’s some of what Globe’s managing director, Alistair Stephens, had to say on the news:

Globe has been working diligently and cooperatively with all stakeholders for many years to achieve grant of a  mining licence for the Kanyika Niobium Project. Formal approval from the Malawi Government’s Mineral Resources Committee to grant the Mining Licence is a significant step forward for the company’s goal of becoming a niobium producer. I am particularly pleased for the Globe team who have stayed the course despite many obstacles in recent times.

Clearly, investors are over the moon about the news, given the company has more than tripled in valuation just today. At the current share price, Globe Metals & Mining has a market capitalisation of $67.5 million.

The post ASX stock of the day: Globe Metals & Mining (ASX:GBE) shares up 200% appeared first on The Motley Fool Australia.

More reading

• Clinuvel (ASX:CUV) share price lower despite positive update
• Why ASX agricultural shares are high on institutional investors’ radars
• Why the Growthpoint (ASX:GOZ) share price just smashed a 52-week record
• EML Payments (ASX:EML) share price jumps 5% on Q3 trading update
• Here’s why this ETF could be a top option for ASX investors

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3z5iAwl

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is under pressure on Monday despite the release of a positive announcement.

The biopharmaceutical company’s shares are down 2.5% to $28.07 in afternoon trade.

Despite this, the Clinuvel share price is still up an impressive 23% since the start of the year.

What did Clinuvel announce?

This morning Clinuvel announced that its afamelanotide drug has been administered to a first patient diagnosed with an acute arterial ischaemic stroke (AIS).

The release explains that the patient was enrolled in a world’s first clinical trial (CUV801) after suffering an acute stroke and being admitted to a specialist neurological hospital in Australia to receive treatment.

Clinuvel advised that a total of six adult AIS patients will be evaluated in the Phase II CUV801 study, which is focusing on the safety and therapeutic potential of afamelanotide in patients who are ineligible for standard stroke therapy.

Clinuvel’s Clinical Operations Manager, Dr Pilar Bilbao, said: “The immediate aim in acute AIS treatment, is to bring back the patient’s neurological and muscular functions by improving the blood flow to the affected site of the brain. Our unambiguous aim is to develop a treatment for 70% to 80% of the stroke patients who currently have no alternative treatment.”

Why afamelanotide?

According to the release, scientific progress has demonstrated melanocortins, including afamelanotide, provide a positive effect on the central nervous system.

Afamelanotide is known to offer neuroprotection and act as a potent anti-oxidative hormone. The drug also possesses further therapeutic benefits, activating vessels, reducing fluid formation, protecting critical nerve and brain tissue, and restoring the blood brain barrier. The latter is a critical defence mechanism protecting the brain.

If successful, this could be a lucrative therapy for Clinuvel. The company notes that AIS accounts for approximately 85% of the 15 million strokes suffered worldwide each year. Despite its prevalence, treatment options are limited and in Europe, over 85% of AIS cases presenting to hospitals are not eligible for current standard of care treatment.

The post Clinuvel (ASX:CUV) share price lower despite positive update appeared first on The Motley Fool Australia.

More reading

• Why ASX agricultural shares are high on institutional investors’ radars
• Why the Growthpoint (ASX:GOZ) share price just smashed a 52-week record
• EML Payments (ASX:EML) share price jumps 5% on Q3 trading update
• Here’s why this ETF could be a top option for ASX investors
• How much is the BHP (ASX:BHP) dividend worth today?

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3uV5vm1